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Abstract: Maspin is a unique member of the serpin family involved in regulation of cell migration, apoptosis and angiogenesis
in breast and prostate cancers. In this study maspin expression in comparison with c-erbB-2 (HER2/neu) oncogene expression
and microvessel density was investigated. The examined material included specimens of primary invasive ductal breast cancer
derived from 69 patients. They were analyzed immunocytochemically to assess maspin and c-erbB-2 expression, as well as
microvessel density using endothelium marker CD31. In the studied cancers, maspin expression in cancer cells was detected
in more than half of the cases (50.73%). Although statistically insignificant (p=0.27), maspin expression showed decreasing
tendency with the increase of tumor grade. C-erbB-2 oncogene expression was observed in 78.26% of the examined cancers.
Statistically significant positive correlation was found between c-erbB-2 expression and tumor grade (p<0.005). Analysis of
the dependence between maspin and c-erbB-2 expression exhibited statistically significant inverse correlation (p<0.001). Mean
microvessel density (MVD) of the studied cancers was 71.64 (SD=19.36). MVD decreased with the increase of maspin
expression, whereas in the cases showing c-erbB-2 overexpression MVD was clearly higher. Both correlations were statistically
significant (p<0.005). In conclusion, it could be stated that increase in maspin expression is associated with weaker expression
of c-erbB-2 oncogene and lower microvessel density, which implies a significant role of maspin in tumor biology. However,
the exact mechanism of maspin action (including its potential role in angiogenesis), as well as the assessment of its prognostic
significance in breast cancer require further studies.
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Introduction 
Maspin is a 42 kDa protein belonging to a big family of
serine protease inhibitors (serpins). It exhibits strong
structural homology with other members of this family,
such as plasminogen-activator inhibitors 1 and 2 (PAI-1
and PAI-2), and α1-antitrypsin. For the first time, maspin
was identified in normal mammary gland in myoepithe-
lial cells, and later in breast cancers [31, 39], hence its
name (mammary serine protease inhibitor). 
Little is known about physiological role and the
mechanism of maspin functioning. 
Numerous studies suggest that a suppressive function
of maspin in cancers results in the inhibition of their
invasiveness and metastasis. The probable mechanism
underlying this process includes the limitation of cell
motility through the inhibition of the cascade of extra-
cellular plasminogen activation [2, 4, 19, 32]. Besides,
maspin has been shown to participate in angiogenesis
inhibition [38], and in sensitizing cells to proapoptotic
factors [11]. Therefore, maspin can potentially contribu-
te to the inhibition of cancer development through va-
rious mechanisms.
Data concerning the role and clinical significance of
maspin in human breast cancer are equivocal. Some
experiments have demonstrated inverse correlation be-
tween the decrease in maspin expression, and increase
in breast cancer malignancy and poor clinical course of
the disease [5, 15, 39]. However, other studies suggest
that strong maspin expression is a poor prognostic factor
in breast cancer [34].
Little information has been accumulated about cor-
relation between maspin expression and classical pro-
gnostic factors in breast cancer, such as tumor stage,
estrogen and progesterone receptors, or c-erbB-2, and
p53 expression. Moreover, the obtained results are often
contradictory [3, 10, 15, 22].
C-erbB-2 (HER2/neu) is a transmembrane glycopro-
tein belonging to the family of epidermal growth factor
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receptors (EGFRs) with intrinsic tyrosine kinase activi-
ty. Its over-activation in multiple cancers promotes pro-
liferation of cancer cells and induces their resistance to
apoptosis. Numerous clinical and experimental data im-
ply positive correlation between c-erbB-2 overexpres-
sion, and breast cancer progression and invasiveness
[21]. Signaling pathway triggered by c-erbB-2 controls
expression of various factors associated with cancer
progression and angiogenesis, such as transforming
growth factor - TGFα, vascular endothelial growth fac-
tor - VEGF, plasminogen activator inhibitor-1 (PAI-1),
and trombospondin (TSP) [7]. 
Angiogenesis plays an important role in cancer
progression and metastasis. Cancer growth, invasive-
ness, and capability of metastasizing requires the pre-
sence of new blood vessels. Multiple reports indicate
that determination of tumor microvessel density
(MVD) may be a significant prognostic factor of a
cancer disease course. Studies conducted on breast
[24, 35], colorectal [9, 33], prostate [14] and endome-
trial [13] cancers strongly support the notion that
MVD is a significant and independent prognostic fac-
tor in these diseases.
The location of tumor vessels can be detected on
paraffin sections by immunocytochemical methods with
specific antibodies directed against endothelial cells. In
this study, the expression of CD31 antigen (PECAM1)
was determined, because it is regarded as the most
sensitive immunocytochemical marker of endothelium
[26].
The aim of the present study was to evaluate the
correlation between maspin and c-erbB-2 expression as
related to microvessel density measured by CD31 ex-
pression in primary invasive breast cancer. 
Materials and methods 
The experiments were conducted on 69 specimens of primary inva-
sive ductal breast carcinoma obtained from Lower Silesian Oncology
Center in Wroclaw. Carcinoma specimens were graded according to
the histological criteria due to the modified method of Bloom and
Richardson [8] by two independent pathologists. Clinical charac-
teristics of the patients is shown in Table 1.
Formalin-fixed paraffin-embedded tissue was immediately sec-
tioned. Four µm sections were mounted on Superfrost slides (Menzel
Glaeser, Germany), dewaxed with xylene, and gradually rehydrated.
Activity of endogenous peroxidase was blocked by 30 min incuba-
tion in 1% H2O2. Immunocytochemical reactions were performed
using the following antibodies:
(1) monoclonal mouse antibodies against maspin (clone G167-
70; Pharmingen, USA), 1:1000; 
(2) monoclonal mouse antibodies against c-erbB-2 (clone 353-10;
DakoCytomation, Denmark), 1:100, and 
(3) monoclonal mouse antibodies against CD31 (DakoCytoma-
tion, Denmark), 1:100. 
The antibodies were diluted in the Antibody Diluent, Background
Reducing (DakoCytomation, Denmark). Antigen retrieval was per-
formed by heating in a microwave oven at 800 W in citrate buffer
(pH 6.0) for 10 min. The tested sections were incubated with the
antibodies for 1 h at room temperature. Subsequently, incubations
were performed with biotinylated secondary antibodies (15 min
at room temperature) and with streptavidin-biotinylated peroxi-
dase complex (15 min at room temperature) (LSAB+, HRP,
DakoCytomation, Denmark). DAB (DakoCytomation, Denmark)
was used as a chromogen (7 min at room temperature). All the
sections were counterstained with Meyer’s hematoxylin. In all
cases, negative controls were included in which specific antibody
was substituted by the Primary Mouse Negative Control (Dako-
Cytomation, Denmark).
To estimate maspin staining intensity, a semiquantitative scale
was used, in which points were scored according to the reaction
intensity level as well as the percentage of positive cells. The per-
centage of positive cells was rated as follows: 0 points: 0-5%; 2
points: 6-50%; 3 points: >50%. The staining intensity was rated as
follows: 1 point: weak intensity; 2 points: moderate intensity; 3
points: strong intensity. The points for expression and percentage of
positive cells were added. Tumors were categorized into four groups:
negative - 0 (≤5% cells stained regardless of intensity), weak expres-
sion - 1 (2-3 points), moderate expression - 2 (4-5 points), and strong
expression - 3 (6-7 points). The slides were also examined for the
presence of maspin-positive myoepithelial cells in tumor areas.
The assessment of immunocytochemical reaction demonstrating
c-erbB-2 expression was performed according to FDA (Food and
Drug Administration) recommendations. The specimens were eva-
luated as follows: no staining or membrane staining in less than 10%
of tumor cells - 0; faint and partial membrane staining in more than
10% of tumor cells - 1; moderate complete membrane staining in
more than 10% of tumor cells - 2; strong complete membrane staining
in more than 10% of tumor cells - 3. Values 2 and 3 were considered
to reflect overexpression of c-erbB-2 antigen.
The assessment of microvessel density was performed accor-
ding to the method of Weidner (1995). Areas with the highest
density of vessels showing expression of CD31 antigen were
described as "hot spots". In these areas, at low magnification, sites
of similar shape and size were selected, in which vessels were
counted. Vessel counting was performed under the Olympus BH2
microscope in three separate areas within one chosen "hot spot".
Clusters of stained endothelial cells (observed in cross-section as
separate foci) with arrangement indicating that they belonged to
one vessel were counted as such. Microvessel density was defined
as a sum of the results from three analyzed areas within the "hot
spot". Vessel counting was performed at × 400 magnification in
the field of 0.18 mm2.
Intensity of immunocytochemical reactions was evaluated inde-
pendently by two pathologists. In case of divergences, the evaluation
was repeated using double-headed microscope. 
Statistical analysis of the obtained results was performed using
Statistica 98 PL software (Statsoft Poland). When required χ2 test
and ANOVA test were applied. P<0.005 was considered statistically
significant.
Table 1. Clinicopathologic features of the studied patients with
invasive ductal breast cancer
All patients: 69 (100%)
Age
mean: 53.75 yrs; range: 33-77 yrs
≤50
51-60
>60
30 (43.48%)
21 (30.43%)
18 (26.09%)
Grade
G1
G2
G3
19 (27.54%)
23 (33.33%)
27 (39.13%)
Stage 3a
3b
18 (26.09%)
51 (73.91%)
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Results
Maspin expression
In normal tissue of mammary gland adjacent to cance-
rous sites, maspin expression was limited only to myoe-
pithelial cells surrounding ducts and secretory units
(Fig.1a). In tumor areas, maspin expression, besides
myoepithelial cells, was present also in cancer cells (Fig.
1b, c), or occurred exclusively in cancer cells (Fig. 1d).
Both in myoepithelial and cancer epithelial cells maspin
expression was detected in the cytoplasm and nuclei. No
cells were detected that would show nucleus-limited
maspin expression paralleled by the lack of cytoplasmic
expression.
All of the studied specimens of grade G1 (n=19)
showed maspin-positive myoepithelial cells. In grade
G2 (n=23), 19 specimens exhibited maspin-positive
myoepithelial cells (82.6%), whereas in grade G3
(n=27) no myoepithelial cells showing maspin expres-
sion were found. 
The examined carcinoma specimens varied in ma-
spin expression. No expression (0) was found in 34
specimens (49.27%), weak expression (1) in 9 speci-
mens (13.04 %), moderate expression (2) in 16 speci-
mens (23.18%), and strong expression (3) in 10
specimens (14.49%).
At the particular differentiation stages maspin ex-
pression showed the following mean values: G1 - 1.53
(SD = 1.26); G2 - 1.04 (SD = 1.02); G3 - 0.67 (SD
=1.07). Statistical analysis with χ2 test failed to show
correlation between the intensity of maspin expression
and tumor grade (χ2 = 2.64, p = 0.27). Nevertheless, a
clear tendency can be observed indicating the associa-
tion between stronger maspin expression and higher
differentiation level of the cancer. In G3 grade, percent-
age of the cells showing no maspin expression was the
highest (70.37%), more than twice as high as in G1 grade
(31.60%). Conversely, percentage of the cells exhibiting
strong maspin expression was the least in G3 grade
(7.40%) as compared to G1 (31.60%) and G2 (8.7%)
(Fig. 2a).
C-erbB-2 expression
The product of immunocytochemical reaction indicative
of the expression of c-erbB-2 antigen was present on the
cell surface of cancer cells (membrane staining) (Fig.
1e). Among 69 examined human ductal breast carcino-
mas, 15 specimens (21.74%) failed to show c-erbB-2
-staining (0), 16 specimens (23.19%) exhibited weak
staining (1), 18 specimens (26.01%) showed moderate
staining (2), and 20 specimens (28.98%) exhibited
strong staining (3).
For the specific tumor grades, the level of c-erbB-2
antigen expression showed the following mean values:
G1 - 0.68 (SD=0.75); G2 - 1.83 (SD=0.83); and G3 -
2.11 (SD=1.88).
The least differentiated G3 group contained the hig-
hest percentage (55.5%) of cancer cells showing strong
immunostaining (3) in comparison with more differen-
tiated cancer cells, especially highly differentiated G1
group that did not contain any cells with strong immu-
nostaining. Conversely, G1 group contained the highest
percentage of cells (47.38%) showing no c-erbB-2 ex-
pression, whereas G3 group contained much lower per-
centage of such cells (18.52%) (Fig. 2b).
Inverse correlation between c-erbB-2 expression and
differentiation stage (tumor grade G1-G3) was statisti-
cally significant (χ2= 16.75, p<0.005).
Correlation between maspin and c-erbB-2
expression
In the further analysis, association between c-erbB-2
oncogene and maspin expression in cancer cells was
studied. After comparison of the mean values exhibiting
the intensity of c-erbB-2 expression between four gro-
ups showing different levels of maspin expression (0-3),
the following relations were found: the specimens sho-
wing no maspin expression (0) exhibited high (2.39)
c-erbB-2 expression, the specimens showing weak ma-
spin expression (1) also exhibited high (2.50) c-erbB-2
expression, the specimens showing moderate maspin
expression (2) exhibited moderate (1.35) c-erbB-2 ex-
pression, and the specimens showing strong maspin
expression (3) exhibited weak (0.72) c-erbB-2 expres-
sion.
Inverse correlation was found between c-erbB-2 on-
cogene and maspin expression. Within 43 specimens
exhibiting no or faint maspin expression (0 and 1), 8
specimens (18.61%) showed no or faint c-erbB-2 ex-
pression (0 and 1), whereas 35 specimens (81.39%)
showed overexpression of c-erbB-2 (2 and 3). Within
the group of 26 specimens exhibiting moderate or strong
maspin expression (2 and 3), in 23 specimens (88.46%)
no or faint expression of c-erbB-2 was observed (0 and
1), whereas only in 3 specimens (11.54%) c-erbB-2
oncogen showed overexpression (2 and 3) (Fig. 2c).
These correlations were statistically significant (χ2 =
22.29, p<0.001).
Microvessel density (MVD) in relation to
maspin and c-erbB-2 expression
All the studied specimens were immunopositive for
CD31 antigen. Immunostaining was observed only in
endothelial cells of the vessels (Fig. 1f). Mean MVD of
the studied cancers calculated from three counts was
71.64 (SD=19.36).
MVD decreased with the increase in maspin expres-
sion (Fig. 3a). Mean MVD values in the groups with
different intensity of maspin expression (0-3) were as
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Fig. 1. Immunocytochemical demonstration of maspin (a, b, c, d), c-erbB-2 oncogene (e), and microvasculature (f) in primary invasive breast
cancers. In the areas of normal mammary gland tissue, maspin is present only in myoepithelial cells (a). In the cancerous areas, maspin is
also present in cancer cells (b, c) or occurs exclusively in cancer cells (grade G3) (d). Micrograph e shows breast cancer cells exhibiting
c-erbB-2 oncogene overexpression. Micrograph f demonstrates blood vessels with CD31-stained endothelium. Magnifications: a - × 400, b
- × 200, c - × 600, d and e - × 400, f - × 200.
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follows: 0 - 94.00 (SD=14.19), 1 - 89.10 (SD=13.46), 2
- 65.39 (SD=13.79,), 3 - 51.39 (SD=2 .63). These diffe-
rences showed statistical significance (ANOVA,
F=28.47, p<0.005).
There was also a correlation between MVD and
c-erbB-2 antigen expression. Mean MVD values in four
groups differing in c-erbB-2 expression (0-3) were as
follows: 0 - 54.60 (SD=9.74), 1 - 55.80 (SD=10.75), 2 -
75.61 (SD=13,36), 3 - 97.80 (SD=7.57). These differen-
ces were statistically significant (ANOVA, F=55.55,
p<0.005); especially MVD in the groups with c-erbB-2
overexpression (2 and 3) was clearly higher in compari-
son with the groups with weak c-erbB-2 expression (0
and 1) (Fig. 3b).
Discussion
More than a half of the studied specimens of human
ductal breast carcinoma (50.73%) exhibited maspin ex-
pression in cancer cells. In spite of the lack of statistical
significance, the results show tendency indicating that
weaker maspin expression is associated with lower de-
gree of histological differentiation. However, despite the
highest percentage of specimens showing no maspin
expression within the least differentiated group (G3)
(above 70%), nearly 30% of the specimens exhibited
moderate or strong maspin expression in cancer cells (2
or 3), whereas there were no cases with weak staining
(1).
Little information is available on the relationships
between maspin expression in mammary cancer cells
and prognostic factors, as well as clinical data in the
course of breast cancer disease. What makes this prob-
lem even more unclear, the reported findings are often
contradictory. Statistically significant correlations be-
tween maspin expression and tumor grade were obser-
ved in prostate cancer [17] and oral squamous cell
carcinomas [37], as well as in animal models of breast
cancer [27]. Investigations conducted on breast cancer
cell lines and on primary breast carcinomas showed that
the decrease in maspin expression was associated with
the transition of cancers in situ to invasive form and that
Fig. 2. a. Profile of maspin expression in different tumor grades
(G1-3). 0 - no staining, 1 - weak staining, 2 - moderate staining, 3 -
strong staining. b. Profile of c-erbB-2 oncogene expression in diffe-
rent tumor grades. 0 - no staining, 1 - weak staining, 2 - moderate
staining, 3 - strong staining. c. Relation between maspin and c-erbB-2
oncogene expression in the studied cancers. (0,1) - no or weak
staining, (2,3) - moderate or strong staining. 
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the lack of expression was associated with highly meta-
static carcinomas [5, 15, 39]. Therefore, in the light of
some investigations, low maspin expression is potential-
ly a poor prognostic factor [10, 15, 16]. On the other
hand, Umerika et al. [34] and Bièche et al. [3] obtained
opposite results; they reported that maspin overexpres-
sion was associated with poor prognosis of breast cancer
disease, as well as with short survival rates of patients.
Similar results were obtained by Kim et al. [12], who
observed the highest percentage of maspin-positive cells
within low-differentiated breast carcinomas, and high
maspin expression proved to be a poor prognosis factor.
The discrepancies concerning the significance of ma-
spin in breast cancer prognosis can result from differences
in experimental design, including different material - va-
rious cancer types used in studies, as well as different
methods applied for the estimation of maspin expression.
A separate issue concerns maspin expression in
myoepithelial cells present within the tumor area of the
studied cancers. In our material undifferentiated carci-
nomas (G3) did not show the presence of maspin-posi-
tive myoepithelial cells, whereas in G1 grade such cells
were found in all the examined cases.
In normal mammary gland, only myoepithelial cells
are able to synthesize maspin. Since maspin is one of the
most sensitive and specific markers of myoepithelial
cells [28], it remains unclear whether during transforma-
tion to more aggressive cancer form, myoepithelial cells
undergo atrophy within tumor tissue, or whether they
loose their ability to synthesize maspin.
Interaction between myoepithelial and cancer cells is
one of the significant local mechanisms regulating tumor
development [10]. Due to their location, myoepithelial
cells create a natural barrier separating cancer cells from
connective tissue stroma and blood vessels, what hinders
progression of cancers from in situ to the invasive form.
Numerous recent experiments suggest that myoepithe-
lial cells inhibit cancer progression through the inhibi-
tion of epithelial cells proliferation, apoptosis induction
and angiogenesis inhibition [23]. The majority of the
suppressor functions ascribed to myoepithelial cells
overlaps biological activities of maspin in tumor biolo-
gy. Maspin is secreted to the surface of myoepithelial
cells [25], and paracrinally affects the neighboring epit-
helial cells, as well as the endothelium of the adjacent
blood vessels.
These observations suggest that maspin expression
in cancer cells is initiated in response to the atrophy of
myoepithelial cells or the cessation of maspin synthesis
in these cells.
Data obtained in this study indicate inverse correla-
tion between maspin and c-erbB-2 expression in breast
cancer cells. On the basis of immunocytochemical ana-
lysis it is difficult to conclude whether this correlation
results from a direct dependence or reflects an antago-
nistic involvement of both factors in a common metabo-
lic processes such as angiogenesis regulation. Since
maspin is present mainly on the cell surface [25, 30], it
may directly affect the activity of c-erbB-2 receptor, thus
modulating metabolic processes triggered by this recep-
tor. However, the molecular mechanism of this rela-
tionship has not been investigated and further, more
detailed studies are needed to verify this hypothesis.
The analysis of microvessel density of the studied
cancers suggests that the increase in maspin expression
is associated with a significant reduction of microvessel
density. Similar results were obtained in experimental
studies where exogenous maspin significantly reduced
the number of blood vessels in prostate tumors implan-
ted into athymic mice, as well as completely blocked
neovascularization of cornea induced in vivo by bFGF
[38].
Fig. 3. Microvessel density (MVD) of the studied cancers in comparison with maspin and c-erbB-2 oncogene expression. a - MVD versus
maspin. b - MVD versus c-erbB-2 oncogene.
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Unlike in the case of maspin, microvessel density
increased with the increase in c-erbB-2 expression. Mo-
reover, it was clearly higher in the cancers showing
c-erbB-2 overexpression (2 and 3). These observations
are in agreement with other studies exhibiting that c-
erbB-2 overexpression in cancer cells promotes neoan-
giogenesis through the release of angiogenic cytokines
(VEGF, Ang-2) [1]. 
The mechanism of angiogenesis inhibition by maspin
is not fully elucidated. Some data suggest that maspin
bound by endothelium may directly modify cell respon-
se to receptor-mediated processes regulating angiogene-
sis, similarly as in the case of CD 36 effect on
trombospondin activity [6]. 
In vitro and in vivo studies suggest that maspin is an
efficient inhibitor of angiogenesis induced by bFGF, as
well as by cancer cell line LNCaP secreting VEGF [38].
Activated c-erbB-2 oncogene increases the secretion of
VEGF by cancer cells [1, 20], which results in angioge-
nesis induction. It might be proposed that maspin would
inhibit angiogenesis by affecting c-erbB-2 receptor and
blocking the signaling pathway leading to VEGF secre-
tion.
Nevertheless, the interdependence between maspin
and c-erbB-2 expression might be more complicated and
involve other processes associated with breast cancer
development such as regulation of the expression of
urokinase-type plasminogen activators and their recep-
tors (uPA, uPAR), which would affect cell motility and
adhesiveness. Moreover, the interplay between the two
factors may modulate sensitivity of cancer cells to pro-
and antiapoptotic agents [11, 18, 21]. 
In conclusion, it can be assumed that maspin expres-
sion is associated with fainter c-erbB-2 expression, as
well as decreased microvessel density in breast cancers.
It implies a significant role of maspin in breast cancer
development. Therefore, a deeper insight into the me-
chanisms underlying mutual relationships between ma-
spin expression, c-erbB-2 expression and neoangio-
genesis would allow better understanding of a complex
process of cancer development. However, more studies
are needed to elucidate the exact maspin function in this
process, as well as its potential prognostic significance.
References
[ 1] Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendel-
sohn J, Kumar R (2000) Vascular endothelial growth factor
upregulation via p21-activated kinase-1 signalling regulates
heregulin-(1-mediated angiogenesis. J Biol Chem 275:
39451-39457
[ 2] Bass R, Fernandez AM, Ellis V (2002) Maspin inhibits cell
migration in the absence of protease inhibitory activity. J Biol
Chem 277: 46845-46848 
[ 3] Bièche I, Girault I, Sabourin J-C, Tozlu S, Driouch K, Vidaud
M, Lidereau R (2003) Prognostic value of maspin mRNA
expression in ERα-positive postmenopausal breast carcinomas.
Brit J Cancer 88: 863-870
[ 4] Biliran HJr, and Sheng S (2001) Pleiotrophic inhibition of
pericellular urokinase-type plasminogen activator system by
endogenous tumor suppressive maspin. Cancer Res 61: 8676-
8682
[ 5] Czerwenka KF, Manavi M, Hosmann J, Jelincic D, Pischinger
KI, Battistutti WB, Behnam M, Kubista E (2001) Comparative
analysis of two-dimensional protein patterns in malignant and
normal human breast tissue. Cancer Detect Prev 25: 268-279
[ 6] Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA,
Bouck NP (1997) CD36 mediates the in vitro inhibitory effects
of thrombospondin-1 on endothelial cells. J Cell Biol 138:
707-717
[ 7] Eccles SA (2001) The role of c-rebB-2/HER2/neu in breast
cancer progression and metastasis. J Mammary Gland Biol
Neoplasia 6: 393-406
[ 8] Elston CW (1987) Grading of invasive carcinoma of the breast.
In: Diagnostic histopathology of the breast. Page DL, Anderson
TJ [Eds],  Churchill Livingstone, Edinburgh, pp 300-311 
[ 9] Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N,
O’Malley FP (1996) Tumor angiogenesis predicts recurrence in
invasive colorectal cancer when controlled for Dukes staging.
Am J Surg Pathol 20: 1260-1265
[10] Hojo T, Akiyama Y, Nagasaki K, Maruyama K, Kikuchi K,
Ikeda T, Kitajima M, Yamaguchi K (2001) Association of
maspin expression with the malignancy grade and tumor vascu-
larization in breast cancer tissues. Cancer Lett 171: 103-110 
[11] Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S (2002)
Maspin senstisizes breast carcinoma cell to induced apoptosis.
Oncogene 21: 4089-4098
[12] Kim DH, Yoon DS, Dooley WC, Nam ES, Ryu JW, Jung KC,
Park HR, Sohn JH, Shin HS, Park YE (2003) Association of
maspin expression with the high histological grade and lym-
phocyte-rich stroma in early-stage breast cancer. Histopatholo-
gy 42: 37-42
[13] Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Mor-
gan E, Yang JJ, Yordan EL (1996) Angiogenesis factor in
endometrial carcinoma: a new prognostic indicator? Am J Ob-
stet Gynecol 174: 1879-1884
[14] Lissbrant IF, Stattin P, Damber JE, Bergh A (1997) Vascular
density is a predictor of cancer-specific survival in prostatic
carcinoma. Prostate 33: 38-45
[15] Maass N, Hojo T, Rosel F, Ikeda T, Jonat W, Nagasaki K (2001)
Downregulation of the tumor suppressor gene maspin in breast
carcinoma is associated with a higher risk of distant metastasis.
Clin Biochem 34: 303-307
[16] Maass N, Teffner M, Rosel F, Pawaresch R, Jonat W, Nagasaki
K, Rudolph P (2001) Decline in the expression of the serine
proteinase inhibitor maspin is associated with tumour progres-
sion in ductal carcinomas of the breast. J Pathol 195: 321-326
[17] Machtens S, Serth J, Bokermeyer C et al (2001) Expression of
the p53 and maspin protein in primary prostate cancer: correla-
tion with clinical features. Int J Cancer 95: 337
[18] Mazumdar A, Adam L, Boyd D, Kumar R (2001) Heregulin
regulation of urokinase plasminogen activator and its receptor:
human breast epithelial cell invasion. Cancer Res 61: 400-405
[19] McGowen R, Biliran HJr, Sager R, Sheng S (2000) The surface
of prostate carcinoma DU145 cells mediates the inhibition of
urokinase-type plasminogen activator by maspin. Cancer Res
4771-4778
[20] Menard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic
and therapeutic role of HER2 in cancer. Oncogene 29: 6570-
6578
[21] Menard S, Tagliabue E, Campiglio M, Pupa SM (2000) Role of
HER2 gene overexpression in breast carcinoma. J Cell Physiol
182: 150-162
[22] Mirecka J, Libura J, Libura M, Koprowski M, Nowak D, Kedra
B, Popiela T (2001) Morphological parameters of the angioge-
nic response in pancreatic ductal adenocarcinoma - correlation
Maspin, c-erbB-2 and MVD in breast cancer 115
with histological grading and clinical data. Folia Histochem
Cytobiol 39: 335-340
[23] Mohsin SK, Zhang M, Clarck GM, Allred C (2003) Maspin
expression in invasive breast cancer: asociation with other pro-
gnostic factors. J Pathol 199: 432-435
[24] Nguyen M, Lee MC, Wang JL, Tomlinson JS, Shao ZM,
Alpaugh ML, Barsky SH (2000) The human myoepithelial cell
displays a multifaceted anti-angiogenic phenotype. Oncogene
20: 3449-3459
[25] Ogawa Y, Chung YS, Nakata B, Takatsuka S, Maeda K, Sawada
T, Kato Y, Yoshikawa K, Sakurai M, Sowa M (1995) Micro-
vessel quantitation in invasive breast cancer by staining for
factor VIII-related antigen. Br J Cancer 71: 1297-1301
[26] Pemberton PA, Tipton AR, Pawloff N, Erickson JR, Moucha-
beck ZM, Kiefer MC (1997) Maspin is a intracellular serpin that
partitions into secretory vesicles and is present at the cell surfa-
ce. J Histochem Cytochem 45: 1697-1706
[27] Poncelet Ch, Madelenat P, Feldman G, Walker F, Darai E
(2002) Expresion of von Willebrand’s factor, CD34, CD31, and
vascular endothelial growth factor in uterine leiomyomas. Fertil
Steril 78: 581-586
[28] Reddy KB, McGowen R, Schuger L, Visscher D, Sheng S
(2001) Maspin expression inversely correlates with breast tu-
mor progression in MMTV/TGF-alpha transgenic mouse mo-
del. Oncogene 20: 6538-6543 
[29] Reis-Filho J, Milanezi F, Paredes J, Silva P, Pereira E, Mareda
S, de Carwalho L, Schmitt F (2003) Novel and classic myoepit-
helial/system cell markers in metaplastic carcinomas of the
breast. Appl Immunohistochem Mol Morphol 11: 1-8 
[30] Sheng S, Carey J, Seftor E, Dias L, Hendrix MJ, Sager R (1996)
Maspin acts at the cell membrane to inhibit invasion and motility
of mammary and prostatic cancer cells. Proc Nat Acad Sci USA
93: 11669-11674
[31] Sheng S, Pemberton PA, Sager R (1994) Production, purifica-
tion and characterization of recombinant maspin proteins. J Biol
Chem 269: 30988-30993
[32] Sheng S, Truong B, Fredrickson D, Wu R, Pardee AB, Sager R
(1998) Tissue-type plasminogen activator is a target of the
tumor suppressor gene maspin. Proc Natl Acad Sci USA 95:
499-504
[33] Tomisaki S, Ohno S, Ichiyoshi Y, Kuwano H, Maehara Y,
Sugimachi K (1996) Microvessel quantification and its possible
relation with liver metastasis in colorectal cancer. Cancer 77:
1722-1728
[34] Umerika Y, Ohi Y, Sagara Y, Yoshida H (2002) Expression of
maspin predicts poor prognosis in breast cancer patients. Int J
Cancer: 100: 452-455
[35] Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J
(1993) Tumor angiogenesis correlates with metastasis in inva-
sive prostate carcinoma. Am J Pathol 143: 401-409
[36] Weidner N (1995) Current pathologic methods for measuring
intratumoral microvessel density within breast carcinoma and
other solid tumors. Breast Cancer Res Treat 36: 169-180
[37] Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, El-Na-
ggar A, Hung MC (2000) High tumoral maspin expression is
associated with improved survival of patiens with oral squamo-
us cell carcinoma. Oncogene 19: 2398-2403
[38] Zhang M, Volpert O, Shi YH, Bouck N (2000) Maspin is an
angiogenesis inhibitor. Nat Med 6: 196
[39] Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S,
Rafidi K, Seftor E, Sager R (1994) Maspin, a serpin with
tumor-suppressing activity in human mammary epithelial cell.
Science 263: 526-529
       Received: December 10, 2004
       Accepted after revision: January 31, 2005
116 M. Sopel et al.
